Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma

Abstract

AbstractObjectivesTo analyze the impact of perioperative characteristics on the risk of recurrence in patients with uterine leiomyosarcomas.MethodsA sub‐analysis of the SARComa of the UTerus (SARCUT) study, which is a multicentric cross‐sectional pan‐European study that included 390 patients diagnosed with leiomyosarcoma, between 2001 and 2007. Perioperative factors related to risk of recurrence and survival were analyzed.ResultsThe 5‐year and 10‐year disease‐free survivals (DFS) were 46% and 55%, respectively. Overall survival at 5 and 10 years was 34% and 47%, respectively. The most important factors related to global recurrence were the incomplete cytoreduction (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.91–4.31); performing bilateral adnexectomy (HR 2.71; 95% CI 1.23–5.93); tumor persistence after any treatment (HR 2.38; 95% CI 1.39–4.06); and adjuvant chemotherapy administration (HR 2.55; 95% CI 1.82–3.58) or adjuvant radiotherapy (HR 2.26; 95% CI 1.53–3.32). The major factors significantly associated with pelvic relapse were tumor persistence after any treatment (HR 3.63; 95% CI 1.83–7.20) and adjuvant radiotherapy (HR 2.74; 95% CI 1.44–5.20). Incomplete cytoreduction was the most important factor associated with distant relapse (HR 1.91; 95% CI 1.22–2.97). The most important factors related to overall survival were tumor persistence after any treatment (HR 4.59; 95% CI 2.51–8.40), incomplete cytoreduction (HR 3.68; 95% CI 2.44–5.56), tumor margin involvement (HR 2.41; 95% CI 1.64–3.55) and adjuvant chemotherapy (HR 1.91; 95% CI 1.31–2.78).ConclusionsComplete cytoreduction is the main prognosis factor impacting the DFS and overall survival of patients with uterine leiomyosarcoma. Adjuvant chemotherapy administration was associated with decreased rates of DFS and overall survival. The adjuvant radiotherapy was associated with a higher risk of global recurrence.